Seminars in Vascular Medicine
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Preface
2002
-
Recent Advances in Thrombosis and Hemostasis—Part IX.
49:670-672.
2023
-
Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study.
49:725-735.
2023
-
Clinical Studies with Anticoagulants that Have Changed Clinical Practice.
49:242-254.
2023
-
Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis.
49:047-054.
2023
-
A Historical Perspective on the Reversal of Anticoagulants.
48:955-970.
2022
-
Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study.
48:446-458.
2022
-
Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis.
47:709-723.
2021
-
New-Onset Atrial Fibrillation in Sepsis: A Narrative Review.
47:018-025.
2021
-
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial.
46:977-985.
2020
-
Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials.
46:908-918.
2020
-
Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism.
46:772-776.
2020
-
Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction.
45:784-792.
2019
-
Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry.
45:793-801.
2019
-
Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review.
45:150-156.
2019
-
Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study.
45:187-195.
2019
-
Erratum: Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment.
45:121-122.
2019
-
Berzelius Symposium 93: International Conference on Thrombosis and Embolism.
43:811-813.
2017
-
Bleeding Complications and Management on anticoagulant therapy.
43:886-892.
2017
-
Recent Advances in Thrombosis and Hemostasis—Part II.
43:809-810.
2017
-
Laboratory Monitoring of Oral Vitamin K Anticoagulation.
43:245-252.
2017
-
Recent Advances in Thrombosis and Hemostasis – Part I.
42:805-807.
2016
-
Optimal Anticoagulation for Pregnant Women with Mechanical Heart Valves.
42:798-804.
2016
-
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature.
42:671-681.
2016
-
Safety of Salvaged Blood and Risk of Coagulopathy in Cardiac Surgery.
42:166-171.
2016
-
Individualizing Factor Replacement Therapy in Severe Hemophilia.
41:864-871.
2015
-
Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk.
41:160-165.
2015
-
Heparin-Induced Thrombocytopenia in Critically Ill Patients.
41:049-060.
2015
-
Venous Thromboembolism Prophylaxis in Critically Ill Patients.
41:068-074.
2015
-
When the Rubber Meets the Road: Adherence and Persistence with Non–Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real World—A Problem or A Myth ?.
40:852-859.
2014
-
Thrombosis: A Major Contributor to Global Disease Burden.
40:724-735.
2014
-
Thrombotic Risk in the Antiphospholipid Syndrome.
40:741-746.
2014
-
Supportive Care in Pediatric Cancer: The Road to Prevention of Thrombosis.
40:371-381.
2014
-
Factor XIII Assays and Associated Problems for Laboratory Diagnosis of Factor XIII Deficiency: An Analysis of International Proficiency Testing Results.
40:232-238.
2014
-
Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry.
40:099-105.
2014
-
von Willebrand Factor: Form for Function.
40:017-027.
2014
-
Genetic Loci Associated with Platelet Traits and Platelet Disorders.
39:291-305.
2013
-
Expert Approaches to Common Bleeding and Thrombotic Problems, Part II.
39:113-116.
2013
-
Optimal Duration of Anticoagulant Therapy.
39:141-146.
2013
-
Acquired Hemophilia A.
38:735-741.
2012
-
Approaches to Diagnosing and Managing Anticoagulant-Related Bleeding.
38:702-710.
2012
-
D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders.
38:673-682.
2012
-
Expert Approaches to Common Bleeding and Thrombotic Problems—Part I.
38:641-644.
2012
-
Laboratory Investigations for Bleeding Disorders.
38:742-752.
2012
-
Perioperative Management of Patients Having Noncardiac Surgery Who Are Receiving Anticoagulant or Antiplatelet Therapy: An Evidence-Based but Practical Approach.
38:652-660.
2012
-
External Quality Assessment of Platelet Disorder Investigations: Results of International Surveys on Diagnostic Tests for Dense Granule Deficiency and Platelet Aggregometry Interpretation.
38:622-631.
2012
-
The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses.
38:07-15.
2012
-
Childhood Immune Thrombocytopenia: A Changing Therapeutic Landscape.
37:745-755.
2011
-
Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis.
37:802-809.
2011
-
Thrombosis in Children.
37:763-761.
2011
-
Heparin-Induced Thrombocytopenia: Real-World Issues.
37:653-663.
2011
-
Piecing Together the Humoral and Cellular Mechanisms of Immune Thrombocytopenia.
37:631-639.
2011
-
Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment.
37:713-720.
2011
-
Thrombocytopenic Platelet Disorders.
37:617-620.
2011
-
Management of Inheritedvon Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients.
37:511-521.
2011
-
New Anticoagulants for Atrial Fibrillation.
35:711-711.
2009
-
Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms.
35:554-559.
2009
-
New Anticoagulants for Atrial Fibrillation.
35:515-524.
2009
-
Diagnostic Assessment of Platelet Disorders: What Are the Challenges to Standardization?.
35:131-138.
2009
-
Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future.
35:127-130.
2009
-
Determinants of Bleeding Risk in Patients on Antithrombotic and Antifibrinolytic Drugs.
34:762-771.
2008
-
Preventing Venous Thromboembolism in Critically Ill Patients.
34:469-474.
2008
-
Hemorrhagic Complications in Pediatric Hematologic Malignancies.
33:408-415.
2007
-
Thromboembolic Complications in Pediatric Hematologic Malignancies.
33:416-426.
2007
-
Platelet Function Testing: Quality Assurance.
33:273-282.
2007
-
A Step Change in Oral Anticoagulation: Lack of Coagulation Monitoring with Ximelagatran.
5:259-265.
2005
-
Ximelagatran in the Clinic: Practical Management of Patients.
5:301-307.
2005
-
Obesity and Cardiovascular Disease: Pathogenic Mechanisms and Potential Benefits of Weight Reduction.
5:25-33.
2005
-
An Overview of the Heparin-Induced Thrombocytopenia Syndrome.
30:273-283.
2004
-
Nonviral Gene Therapy Approaches to Hemophilia.
30:197-204.
2004
-
Low-Molecular-Weight Heparin in Pediatric Patients.
30:31-39.
2004
-
Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy.
30:21-30.
2004
-
Anticoagulation Therapy in Children.
29:425-432.
2003
-
Antiplatelet Agents in Acute Coronary Syndromes.
03:403-414.
2003
-
Low-Molecular-Weight Heparin or Oral Anticoagulation for Secondary Prevention of Deep Vein Thrombosis in Cancer Patients.
29:009-012.
2003
-
New Anticoagulants.
29:619-632.
2003
-
Oral Anticoagulant Initiation: Rationale for the Use of Warfarin Dosing Nomograms.
03:255-260.
2003
-
Oral Anticoagulant Therapy in Patients with Coronary Artery Disease.
03:323-332.
2003
-
Orally Active Direct Thrombin Inhibitors.
03:131-138.
2003
-
Venous Thromboembolism and Its Treatment in High-Risk Groups.
29:001-002.
2003
-
Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?.
29:033-036.
2003
-
Benefit of Selective Factor Inhibition.
28:049-050.
2002
-
Dysglycemia: A Key Cardiovascular Risk Factor.
2:165-174.
2002
-
New Standards in Antithrombotic Therapy: Concepts, Clinical Evidence, and Applications.
28:001-002.
2002
-
Optimizing Prophylaxis of Venous Thromboembolism.
28:025-032.
2002
-
State of the Art-A Journey through the World of Antithrombotic Therapy.
28:003-012.
2002
-
Antithrombotics and Anticoagulants in Coronary Syndromes and Stroke.
Volume 26:085-086.
2000
-
Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness.
Volume 26:0421-0424.
2000
-
The Endothelium and Thrombosis.
26:463-478.
2000
-
The Thrombophilic State Induced by Therapeutic Agents in the Cancer Patient.
25:137-145.
1999
-
Treatment of Venous Thromboembolism in Cancer Patients.
25:245-249.
1999
-
Preclinical differentiation of low molecular weight heparins..
25 Suppl 3:63-72.
1999
-
Pharmacological Actions of Sulodexide.
24:127-138.
1998
-
Thrombin and Antithrombotics.
24:87-91.
1998
-
Prophylaxis of Venous Thromboembolism in Stroke Patients.
23:155-157.
1997
-
Low-Molecular-Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results.
23:77-81.
1997
-
Control Mechanisms in Thrombin Generation.
22:303-308.
1996
-
Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis..
22 Suppl 2:7-12.
1996
-
Neonatal Thrombosis: Are We Doing the Right Studies?.
21:313-316.
1995
-
Anticoagulant Actions of Tissue Factor Pathway Inhibitor on Tissue-Factor-Dependent Plasma Coagulation.
21:240-244.
1995
-
Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia.
20:324-327.
1994
-
Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications.
20:266-273.
1994
-
Prophylactic doses of enoxaparin and heparin inhibit prothrombin activation..
19 Suppl 1:29-30.
1993
-
Hemophilia in the 1990s: Principles of Management and Improved Access to Care.
18:1-10.
1992
-
Thrombin Regulation in Mother and Fetus During Pregnancy.
18:81-90.
1992
-
Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism.
14:41-49.
1988
-
Clinical Use of Low Molecular Weight Heparins and Heparinoids.
14:116-125.
1988
-
Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties.
14:9-17.
1988
-
Lack of Relationship Between Enhanced Bleeding Induced by Heparin and Other Sulfated Polysaccharides and Enhanced Catalysis of Thrombin Inhibition.
12:324-327.
1986
-
Effectiveness of Anticoagulants.
12:21-37.
1986
-
Hemorrhagic Complications of Anticoagulant Therapy.
12:39-57.
1986
-
Heparin-Induced Thrombocytopenia.
12:59-62.
1986
-
Mechanism of Action and Monitoring of Anticoagulants.
12:1-11.
1986
-
Nonhemorrhagic Complications of Anticoagulant Therapy.
12:63-66.
1986
-
Risks and Benefits of Anticoagulant Therapy.
12:67-71.
1986
-
Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate.
11:133-137.
1985
-
Rationale Behind the Development of Low Molecular Weight Heparin Derivatives.
11:13-16.
1985
-
Alloantibodies and Platelet Destruction.
8:105-115.
1982
-
Autoimmune Platelet Destruction: Idiopathic Thrombocytopenic Purpura.
8:83-104.
1982
-
Drug-Induced Platelet Destruction.
8:116-137.
1982
-
Increased Platelet Destruction.
8:75-82.
1982
-
Increased Platelet Destruction in Infancy and Childhood.
8:248-262.
1982
-
Infection-Induced Thrombocytopenia.
8:217-233.
1982
-
Platelet Consumption in Cardiovascular Disease.
8:161-185.
1982
-
Thrombocytopenia in Preeclampsia and Eclampsia.
8:234-247.
1982
-
Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndrome.
8:186-197.
1982
-
Diagnosis of Venous Thromboembolism.
2:203-231.
1976
-
Prevention of Venous Thromboembolism.
2:232-290.
1976
-
Treatment of venous thromboembolic disease..
2:291-331.
1976
-
Thrombolysis with a Combination of Small Doses of Streptokinase and Full Doses of Heparin.
2:14-32.
1975
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)